GALNT3 and cancer: Using the Genomics of Drug Sensitivity in Cancer (GDSC) and The Cancer Genome Atlas (TCGA) databases, we identified 4 biomarkers (CYTH3, GALNT3, S100A14, and ERI1) to predict cisplatin sensitivity.